The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity, sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates, and 95% confidence intervals for rates. The USCS data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System (NVSS).

Cancer was responsible for around 142 deaths per 100,000 population in the United States in 2022. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated 65,790 deaths among men alone in 2024. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as 99 percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around 81 percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. A recent poll indicated that many U.S. adults believed smoking cigarettes and using other tobacco products increased a person’s risk of developing cancer, but a much smaller percentage believed the same for proven risk factors such as obesity and drinking alcohol.

Cancer Rates for Lake County Illinois. Explanation of field attributes: Colorectal Cancer - Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine). This is a rate per 100,000. Lung Cancer – Cancer that forms in tissues of the lung, usually in the cells lining air passages. This is a rate per 100,000. Breast Cancer – Cancer that forms in tissues of the breast. This is a rate per 100,000. Prostate Cancer – Cancer that forms in tissues of the prostate. This is a rate per 100,000. Urinary System Cancer – Cancer that forms in the organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra. This is a rate per 100,000. All Cancer – All cancers including, but not limited to: colorectal cancer, lung cancer, breast cancer, prostate cancer, and cancer of the urinary system. This is a rate per 100,000.

In 2021, Kentucky reported the highest cancer incidence rate in the United States, with around 510 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2021.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

According to Cognitive Market Research, the global Cancer Cachexia market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of XX from 2024 to 2031.

• The global Cancer Cachexia market will expand significantly by XX% CAGR between 2024 and 2031. • North America held a market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Asia Pacific held the major market of more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Latin America's market will have more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • According to Cognitive Market Research, Progestogens is the dominant therapeutic segment for the cancer cachexia market. • According to Cognitive Market Research, Appetite Stimulators is the dominant mechanism action segment for the cancer cachexia market.

MARKET DYNAMICS:

Key Drivers

Increase in the incidence of cancer fuels the demand for Cancer Cachexia Treatment

One of the key drivers behind the significant growth in cancer cachexia treatment is the rising prevalence of cancer globally. As cancer rates continue to increase, particularly in aging populations, the demand for effective cachexia management strategies grows accordingly. For instance. For instance, The International Agency Research on Cancer- Globocan 2020 report states that out of 19,292,789 new cancer cases recognized worldwide in 2020, 9,958,133 deaths were attributed to cancer. There will be 50,550,287 cancer cases worldwide in the next five years, according to forecasts. By 2040, 28,887,940 new cases of cancer are expected worldwide. (Source:https://www.uicc.org/news/globocan-2020-global-cancer-data) Furthermore, according to GLOBOCAN 2020, 495,773 pancreatic, 604,100 esophageal, 1,414,259 prostate, and 1,148,515 colon cancer cases were identified worldwide in 2020, accounting for 2,206771 new cancer cases. Cachexia is very common in patients with the cancer types listed above, so over the next few years, there will be a growing need for cancer cachexia treatment. Thus, the increase in cancer incidence surges demand for advanced therapeutics drugs, which drives the growth of cancer cachexia market.

Key Restrain

The stringent government policies and high cost associated with the treatment hampers Cancer Cachexia market growth

The stringent government policies and the high costs associated with the treatment presents a significant barrier to the growth of the market. Since terminally sick cancer patients are more likely to experience cancer cachexia, yet medications used to treat this disorder typically have to closely follow the same guidelines as other cancer medications. Many countries have lengthy approval processes for pharmaceuticals, particularly those connected to cancer, due to strict regulatory standards. The amount of time needed for countries to approve cancer medications following their current national regulatory criteria varies greatly. For instance, The CHMP in Europe has 210 days to provide its opinion. This is followed by a period of decision-making phase which may extend upto three months. As a result, patients typically acquire access to promising medications (such as those for cancer cachexia) at varying times. This significantly limits the majority of large corporations' capacity marketing ability. Many individuals miss out on potentially necessary treatment that might be utilized to improve their quality of life because cancer cachexia drugs are given to terminally ill patients due to delayed authorization in various nations (Source:https://extranet.who.int/prequal/sites/default/files/document_files/article_58_guidelines.pdf) In addition, the expense of treating cancer patients with cachexia is significantly higher than that of t...

*It is noted that multiple studies reported on more than a single cancer site and the total does not therefore equal 34.1A study reported increased risk for males but no increase for females.2A study reported increased risk for total population, but no increase when examined by gender.3A study reported increased risk for males but no increase for females.

Snapshot img

Cancer Registry Software Market Size 2024-2028

The cancer registry software market size is forecast to increase by USD 97.1 million at a CAGR of 12.75% between 2023 and 2028.

The growing prevalence of cancer cases is the key driver of the cancer registry software market. CDC is a key player, specializing in providing advanced cancer registry software solutions, including Registry Plus. These systems facilitate accurate and efficient data management for healthcare organizations, enabling effective tracking, analysis, and reporting of cancer patient information as well as supporting cancer immunotherapy and cancer diagnostics. By supporting improved patient care and research outcomes, CDC's solutions are essential in addressing the increasing demand for comprehensive cancer data management. 
Additionally, data privacy and security concerns are driving the market, as healthcare organizations prioritize protecting sensitive patient information. These trends are shaping the market, which is expected to continue its growth trajectory In the coming years.

What will be the Size of the Cancer Registry Software Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the increasing incidence of cancer and the need for efficient and accurate data management In the healthcare industry. With the adoption of Electronic Health Records (EHRs) and the shift towards evidence-based medicine, cancer registry software solutions have become essential tools for medical professionals to track cancer treatment, therapeutics, and patient outcomes. 
These solutions enable the collection and analysis of data on cancer prevalence, diagnostics, and specific area-focused cancer incidence. They provide valuable insights into cancer-specific outcomes, including chemotherapy, surgery, supportive treatments, and post-endoscopic resection. Furthermore, regulatory guidance documents mandate the use of cancer registry software to ensure compliance with healthcare standards and reduce healthcare costs.
Medical professionals rely on these software solutions to improve patient care and support the ongoing research and development of new cancer treatments.

How is this Cancer Registry Software Industry segmented and which is the largest segment?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premise
  Cloud


Component

  Commercial
  Public


Geography

  North America

    Canada
    US


  Europe

    Germany
    Italy


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period. Cancer registry software plays a pivotal role in managing data related to cancer cases for government hospitals and third-party agencies. This software facilitates the collection, management, and analysis of data on cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. By identifying trends and patterns, governments and agencies can target high-risk populations, address geographic disparities, and recognize emerging cancer types. Cancer registry software enhances the quality of cancer care by enabling the evaluation of treatment practices against clinical guidelines and benchmarking outcomes against standards. The software supports seamless data integration and interoperability with healthcare systems, ensuring coordinated care for cancer patients.

Medical professionals and patients alike benefit from improved cancer care through evidence-based medicine, cancer-specific outcomes, and research institutes. Software solutions cater to various cancer types, including lung cancer, and support cancer staging, treatment, disease management, diagnostics, chemo, surgery, and supportive therapies. These solutions integrate with electronic health records (EHR), enabling secure data storage and access to essential health information. Data security and security protocols are prioritized to protect patient privacy and prevent medical identity theft. Cancer registry software supports population health management, healthcare cost containment, and chronic disease management. It aligns with healthcare quality goals and streamlines hospital workflows, making it an essential tool for oncology departments, clinics, hospitals, medical practices, pharmaceutical, biotech, and medical de

Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer

Source agency: Health

Designation: National Statistics

Language: English

Alternative title: Statistics on Waiting Times for Suspected and Diagnosed Cancer Patients Annual Report

The online statistics module allows researchers, health professionals and patients to access and review the latest data about cancer in NSW.

The portal allows you to unlock the most recent cancer incidence and mortality data in NSW.

SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

This statistic shows the percentage of the U.S. adult population that has been diagnosed with cancer and those self-reporting the condition as of 2019, including the gender distribution. During this year, 11 percent of the adult population reported that they had cancer. Of these, 51 percent were women.

This map shows the incidence rate per 100,000 for all cancer types by county. Counties are shaded based on quartile distribution. The lighter shaded counties have lower cancer incidence rates. The darker shaded counties have higher cancer incidence rates. New York State Community Health Indicator Reports (CHIRS) were developed in 2012, and are updated annually to consolidate and improve data linkages for the health indicators included in the County Health Assessment Indicators (CHAI) for all communities in New York. The CHIRS present data for more than 300 health indicators that are organized by 15 different health topics. Data if provided for all 62 New York State counties, 11 regions (including New York City), the State excluding New York City, and New York State. For more information, check out: http://www.health.ny.gov/statistics/chac/indicators/. The "About" tab contains additional details concerning this dataset.

This release summarises the diagnoses in 2019 registered by NDRS covering all registerable neoplasms (all cancers, all in situ tumours, some benign tumours and all tumours that have uncertain or unknown behaviours)

Age standardized rate of cancer incidence, by selected sites of cancer and sex, three-year average, census metropolitan areas.

Medical Service Study Areas (MSSAs)As defined by California's Office of Statewide Health Planning and Development (OSHPD) in 2013, "MSSAs are sub-city and sub-county geographical units used to organize and display population, demographic and physician data" (Source). Each census tract in CA is assigned to a given MSSA. The most recent MSSA dataset (2014) was used. Spatial data are available via OSHPD at the California Open Data Portal. This information may be useful in studying health equity.Age-Adjusted Incidence Rate (AAIR)Age-adjustment is a statistical method that allows comparisons of incidence rates to be made between populations with different age distributions. This is important since the incidence of most cancers increases with age. An age-adjusted cancer incidence (or death) rate is defined as the number of new cancers (or deaths) per 100,000 population that would occur in a certain period of time if that population had a 'standard' age distribution. In the California Health Maps, incidence rates are age-adjusted using the U.S. 2000 Standard Population.

Cancer incidence rates

Incidence rates were calculated using case counts from the California Cancer Registry. Population data from 2010 Census and SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators. Yearly SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators for 5-year incidence rates (2013-2017)According to California Department of Public Health guidelines, cancer incidence rates cannot be reported if based on <15 cancer cases and/or a population <10,000 to ensure confidentiality and stable statistical rates.Spatial extent: CaliforniaSpatial Unit: MSSACreated: n/aUpdated: n/aSource: California Health MapsContact Email: gbacr@ucsf.eduSource Link: https://www.californiahealthmaps.org/?areatype=mssa&address=&sex=Both&site=AllSite&race=&year=05yr&overlays=none&choropleth=Obesity

Number of new cases and incidence calculated based on reporting by outpatient specialists for cancer, diabetes and mental health problems.

In a recent report it was shown that the U.S. has the highest prevalence of diagnosed cancer cases among all adults, with around 9 percent of the adult population having some cancer diagnosis. Cancer is the second leading cause of death from chronic diseases worldwide after cardiovascular diseases.

Global cancer risks

Globally, cancer accounts for about 1 in every 6 deaths. Many cancer cases are caused by behavioral and dietary risks including tobacco, alcohol and physical inactivity. The prevalence of tobacco smoking is on the decline and is expected to decline further in the future. Smoking has been linked to lung cancer, other upper respiratory cancers and chronic obstructive pulmonary disease (COPD). Among other cancer risk factors, alcohol consumption has been linked to liver and colorectal cancers, as well as other non-communicable diseases. Many European countries have high rates of alcohol consumption.

Global cancer prevalence

Globally, trachea, bronchus and lung cancers are responsible for the most cancer deaths, followed by liver cancer. Lifestyle modification is one of the easiest ways people can reduce their risk of these types of cancer. Among all cancer patients globally, a majority had a history of alcohol consumption. Similarly, in China, EU5 and Russia, over a quarter of all cancer patients had a history of smoking.

This statistic shows the number of brain and other nervous system cancer deaths in the United States from 1999 to 2021. The highest number of brain and nervous system cancer deaths was 18,034, reported in 2020.

[ARCHIVED] Community Counts data is retained for archival purposes only, such as research, reference and record-keeping. This data has not been maintained or updated. Users looking for the latest information should refer to Statistics Canada’s Census Program (https://www12.statcan.gc.ca/census-recensement/index-eng.cfm?MM=1) for the latest data, including detailed results about Nova Scotia. This table reports cancer rates by primary site and age group. Geographies available: county, district health authorities